- Seliciclib in malignancies
[作者:Aldoss, IT; Tashi, T; Ganti, AK,期刊:Expert opinion on investigational drugs, 页码:1957-1965 , 文章类型: Editorial Material,,卷期:2009年18-12]
- Cyclins and cyclin-dependent kinases (CDK) form a key part of the regulatory proteins that govern the cell cycle. Aberrancy in their function can lead to uncontrolled growth and proliferation of the cells which forms the...
- Arimoclomol: a potential therapy under development for ALS
[作者:Lanka, V; Wieland, S; Barber, J; Cudkowicz, M,期刊:Expert opinion on investigational drugs, 页码:1907-1918 , 文章类型: Editorial Material,,卷期:2009年18-12]
- Arimoclomol, an amplifier of heat shock protein expression involved in cellular stress response, has emerged as a potential therapeutic candidate in amyotrophic lateral sclerosis (ALS) in recent years. Treatment with ari...
- The rationale for mTOR inhibition in epithelial ovarian cancer
[作者:Trinh, XB; van Dam, PA; Dirix, LY; Vermeulen, PB; Tjalma, WAA,期刊:Expert opinion on investigational drugs, 页码:1885-1891 , 文章类型: Review,,卷期:2009年18-12]
- The AKT/mTOR signaling pathway is frequently overexpressed in human epithelial ovarian cancer and an attractive target for therapy. In vivo mouse models were confirmative for in vitro findings, where the administration o...
- Vernakalant hydrochloride for the treatment of atrial fibrillation
[作者:Kozlowski, D; Budrejko, S; Lip, GYH; Mikhaildis, DP; Rysz, J; Raczak, G; Banach, M,期刊:Expert opinion on investigational drugs, 页码:1929-1937 , 文章类型: Editorial Material,,卷期:2009年18-12]
- Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice. Rhythm control strategy for AF is limited by drug toxicity and side effects, and recent trials have shown that this strategy is not...
- Brostallicin (PNU-166196), a new minor groove DNA binder: preclinical and clinical activity
[作者:Lorusso, D; Mainenti, S; Pietragalla, A; Ferrandina, G; Foco, G; Masciullo, V; Scambia, G,期刊:Expert opinion on investigational drugs, 页码:1939-1946 , 文章类型: Editorial Material,,卷期:2009年18-12]
- Brostallicin (PNU-166196), a-bromo-acrylamido tetra-pyrrole derivative, showed high cytotoxic potency and myelotoxicity dramatically reduced compared with other minor groove DNA-binding agents. In the presence of high in...
|